Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb:62:103-108.
doi: 10.1016/j.coph.2021.11.008. Epub 2021 Dec 26.

Targeting PKC in microglia to promote remyelination and repair in the CNS

Affiliations
Review

Targeting PKC in microglia to promote remyelination and repair in the CNS

Paul M Kim et al. Curr Opin Pharmacol. 2022 Feb.

Abstract

Microglia and CNS-infiltrating macrophages play significant roles in the pathogenesis of neuroinflammatory and neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Prolonged and dysregulated inflammatory responses by these innate immune cells can have deleterious effects on the surrounding CNS microenvironment, which can worsen neurodegeneration and demyelination. However, although chronic activation of pro-inflammatory microglia is maladaptive, other functional microglial subtypes play beneficial roles during CNS repair and regeneration. Therefore, there is a tremendous interest in understanding the underlying mechanism of the activation of these reparative/regenerative microglia. In this review, we focus on the potential role of PKC, a downstream signaling molecule of TREM2 and PLCγ2, and PKC modulators in promoting the activation of reparative/regenerative microglial subtypes as a novel therapy for neuroinflammatory and neurodegenerative diseases.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement Johns Hopkins University has filed a patent on the application of bryostatin-1 and its derivatives for multiple sclerosis and other disorders, and P.M.K. and M.D.K. are co-inventors on this patent.

Publication types